전화로 문의
무료
견적
교정 할인


1544
9241
축! 학술번역 저널 게재

  • 저자: Ji Hoon Seo
    분야: Materials Science
    출간저널: Nano Energy
    임팩트팩터: 10.325

  • 저자: Hyun-soo Kim
    분야: Biochemistry, Genetics, and Molecular Biology
    출간저널: Oncotarget
    임팩트팩터: 6.359

  • 저자: Yoonsung Park
    분야: Medicine
    출간저널: Inhalation Toxicology
    임팩트팩터: 2.26

학술번역 샘플(의학논문번역)


 

원문 만성 신질환자에서 빈혈에 대한 페기네사타이드(peginesatide)의 효능은 2상 임상시험을 통해 입증되었다. 시약투여 전 12주 동안 투석과 조혈자극제 치료를 모두 안 받은 환자들이 초기 페기네사타이드 용량(체중대비용량, 절대용량)과 투여경로(정맥주사, 피하주사), 투여빈도(2주 1회, 4주 1회)에 따라 10군으로 순차적으로 배정되었다. 전체 환자 중에서는 96%의 환자에서 헤모글로빈 반응이 나타났다. 헤모글로빈의 증가에서는 용량반응관계가 보였다. 피하주사나 정맥주사를 유사한 용량으로 투여했을 경우 두 환자군에서 비슷한 수준의 헤모글로빈 반응이 나타났다. 헤모글로빈의 빠른 상승과 1 g/dL 이상의 헤모글로빈 변동은 4주 1회 투여하는 환자보다 2주 1회 투여하는 환자에서 더 많이 일어나는 경향이 있었다. 본 연구는 비투석 만성 신질환자에서 4주 1회 페기네사타이드를 투여하는 것이 헤모글로빈 수치를 증가시키거나 유지하는 데 효과적이라는 것을 처음으로 입증했다는 점에서 의미가 있다. 에포에틴 알파(epoetin alfa) 치료 받고 있는 투석 환자는 성공적으로4주 1회의 페기네사타이드 치료로 바꿀 수 있다는 것이 3상 임상시험을 통해 밝혀졌다.
Reference: Source: >http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377433/

의학번역에디티지 5단계 번역 프로세스 중 1, 2단계는 고객님의 학문 분야에 맞는 학술 전문 번역가가 1차 원문 번역을 진행한 후 번역 리뷰어에 의한 번역본 검토까지 2중 번역으로 철저하게 원문과 대조하여 작업합니다.

원문번역 The efficacy of peginesatide in the treatment of anemia in patients with CKD is proven in a Phase 2 clinical trial. Patients who had received neither dialysis nor an erythropoiesis-stimulating agent in the 12 weeks prior to the administration of the test drug were sequentially assigned to one of ten groups according to initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and frequency (once every-2-week vs. every-4-week dosing). In all patients, 96% showed a hemoglobin (Hb) response, and Hb increase showed a dose-response relationship. When similar dose was given by intravenous or subcutaneous injection, both patient groups showed a similar level of Hb response. There was a tendency for the patients who received once every-4-week dosing to show more rapid Hb elevation and fluctuation in Hb over 1 g/dL than in patients who received once every-2-week dosing. The significance of the present study is that it was the first study to prove that once every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis CKD patients. It was shown in a Phase 3 clinical trial that dialysis patients being treated with epoetin alfa can successfully transition to once every-4-week dosing of peginesatide.

번역본 검토 The efficacy of peginesatide in the treatment of anemia in patients with chronic kidney disease (CKD is) has been proven in a Phase 2 clinical trial. Patients who had received neither dialysis nor an erythropoiesis-stimulating agent in the 12 weeks prior to the administration of the test drug were sequentially assigned to one of ten groups according to initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (once every-2-week vs. every-4-week dosing). InAmong all patients, 96% showed a hemoglobin (Hb) response, and Hbthe increase in Hb showed a dose-response relationship. When similar dose was givenadministered by intravenous or subcutaneous injection, both patient groups showed a similar level of Hb response. There was a tendency for the patients who received once every-4-week dosing to show more rapid Hb elevation and fluctuation in Hb over 1 g/dL than in patients who received once every-2-week dosing. The significance of the present study is that it was the first study to prove that once every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis CKD patients. It was shown in a Phase 3 clinical trial that dialysis patients being treated with epoetin alfa can successfully transition to once every-4-week dosing of peginesatide.

의학번역에디티지 5단계 번역 프로세스 중 3,4,5단계는 고객님의 학문 분야에 맞는 석박사 원어민 에디터 및 리뷰어가 저널에서 요구하는 수준의 영문 원고로 맞추어 드립니다. 프리미엄 교정에서는 논리의 흐름 및 기승전결의 구조까지 점검되며 영문에 한하여 무료 재교정 범위에 충족하는 경우 365일 무료 재교정이 제공됩니다.

프리미엄교정 Thise study aimed to test the efficacy of peginesatide in the treatingment of anemia in patients with chronic kidney disease (CKD) has been proven in by using a Phase 2 clinical trial. Our study population consisted of Ppatients who had were not received neither on dialysis nor or received an erythropoiesis-stimulating agent in the 12 weeks prior to the administeringration of the test drug. were The population was divided intosequentially assigned to one of ten groups cohorts according to that differed in the initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (once every-2-week vs. every-4-week dosing); each patient was sequentially assigned to a cohort. Among all patients, 96% showed a hemoglobin (Hb) response, and the increase in Hb showed an evident dose-response relationship was observed. The Hb responses were similar Wwhen similar the doses was administered by intravenous or and subcutaneous injections, were similar both patient groups showed a similar level of Hb response. There was a tendency for tThe patients who received once every-4-week dosing tended to show more rapid Hb elevation and fluctuation in Hb of over 1 g/dL than in the patients who received once every-2-week dosing. To the best of our knowledge, The significance of the present study is that it was the first study to prove that once every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis CKD patients not undergoing dialysis. It was shown in aA Phase 3 clinical trial showed that dialysis patients being treated with epoetin alfa can successfully transition to once every-4-week dosing of peginesatide.

최종검토 This study aimed to test the efficacy of peginesatide in treating anemia in patients with chronic kidney disease (CKD) by using a Phase 2 clinical trial. Our study population consisted of patients who were not on dialysis or received an erythropoiesis-stimulating agent in the 12 weeks prior to administering the test drug. The population was divided into ten cohorts that differed in the initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (every-2-week vs. every-4-week dosing); each patient was sequentially assigned to a cohort. Among all patients, 96% showed a hemoglobin (Hb) response, and an evident dose-response relationship was observed. The Hb responses were similar when the doses administered by intravenous and subcutaneous injections were similar. The patients who received every-4-week dosing tended to show more rapid Hb elevation and fluctuation in Hb of over 1 g/dL than the patients who received every-2-week dosing. To the best of our knowledge, the present study is the first to prove that every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in CKD patients not undergoing dialysis. A Phase 3 clinical trial showed that dialysis patients being treated with epoetin alfa can successfully transition to every-4-week dosing of peginesatide.

의학논문번역에디티지 5단계 번역 프로세스 중 3,4,5단계는 고객님의 학문 분야에 맞는 석박사 원어민 에디터 및 리뷰어가 저널에서 요구하는 수준의 영문 원고로 맞추어 드립니다. 일반 교정의 경우 영문에 한하여 재교정 시 60% 할인이 제공됩니다.

일반교정 A Phase 2 clinical trial showed thatThe efficacy of peginesatide was efficacious in the treatingment of anemia in patients with chronic kidney disease (CKD) has been proven in a Phase 2 clinical trial. Patients who had were not received neither on dialysis nor or received an erythropoiesis-stimulating agent in the 12 weeks prior to the administration of the test drug were sequentially assigned to one of ten groups cohorts according to the initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (once every-2-week vs. every-4-week dosing). Among all patients, 96% showed a hemoglobin (Hb) response, and the increase in Hb showed an evident dose-response relationship was observed. When similar the doses was administered by intravenous or and subcutaneous injections were similar, both the patient groupscohorts showed a similar level of Hb response. There was a tendency for the patients who received once every-4-week dosing to show more rapid Hb elevation and fluctuation in Hb of over 1 g/dL than in patients who received once every-2-week dosing. The significance of the present study is that it wais the first study to prove that once every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis CKD patients. It was shown in a Phase 3 clinical trial that dialysis patients being treated with epoetin alfa can successfully transition to once every-4-week dosing of peginesatide.

최종검토 A Phase 2 clinical trial showed that peginesatide was efficacious in treating anemia in patients with chronic kidney disease (CKD). Patients who were not on dialysis or received an erythropoiesis-stimulating agent in the 12 weeks prior to the administration of the test drug were sequentially assigned to one of ten cohorts according to the initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (every-2-week vs. every-4-week dosing). Among all patients, 96% showed a hemoglobin (Hb) response, and an evident dose-response relationship was observed. When the doses administered by intravenous and subcutaneous injections were similar, the cohorts showed a similar level of Hb response. There was a tendency for the patients who received every-4-week dosing to show more rapid Hb elevation and fluctuation in Hb of over 1 g/dL than in patients who received every-2-week dosing. The significance of the present study is that it is the first study to prove that every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis CKD patients. It was shown in a Phase 3 clinical trial that dialysis patients being treated with epoetin alfa can successfully transition to every-4-week dosing of peginesatide.


무료 견적 신청